Promotion and prevention of autoimmune disease by CD8+ T cells

Journal of Autoimmunity

Volumn 45, Issue , 2013, Pages 68-79

  Gravano, David M ^a   Hoyer, Katrina K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune disease; CD8+ T cell; Tolerance

Indexed keywords

AUTOANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; TARGET CELL;

AIHA; ALPS; ANTIGEN PRESENTING CELLS; APC; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CD8+ T CELL; CTL; CYTOKINE PRODUCING CD8+ EFFECTORS; CYTOTOXIC T LYMPHOCYTES; EAE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HLA; HUMAN LEUKOCYTE ANTIGEN; LCMV; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MBP; MHC; MOG; MPP; MS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN PROTEOLIPID PROTEIN; RA; REGULATORY T CELL; RHEUMATOID ARTHRITIS; SLE; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL RECEPTOR; T1D; TC; TCR; TISSUE RESTRICTED ANTIGENS; TOLERANCE; TRA; TREG; TYPE 1 DIABETES;

ANIMALS; AUTOIMMUNE DISEASES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; T-LYMPHOCYTES, REGULATORY;

EID: 84884289195     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.06.004     Document Type: Review

References (151)

1. Klein J., Sato A. The HLA system. Second of two parts. New England Journal of Medicine 2000, 343:782-786.
2. Nejentsev S., Howson J.M., Walker N.M., Szeszko J., Field S.F., Stevens H.E., et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007, 450:887-892.
3. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
4. Willcox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clinical and Experimental Immunology 2009, 155:173-181.
5. Wong C.P., Stevens R., Long B., Li L., Wang Y., Wallet M.A., et al. Identical beta cell-specific CD8(+) T cell clonotypes typically reside in both peripheral blood lymphocyte and pancreatic islets. Journal of Immunology (Baltimore, Md: 1950) 2007, 178:1388-1395.
6. Lucchinetti C.F., Popescu B.F., Bunyan R.F., Moll N.M., Roemer S.F., Lassmann H., et al. Inflammatory cortical demyelination in early multiple sclerosis. New England Journal of Medicine 2011, 365:2188-2197.
7. Rep M.H., van Oosten B.W., Roos M.T., Ader H.J., Polman C.H., van Lier R.A. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. Journal of Clinical Investigation 1997, 99:2225-2231.
8. Coles A.J., Compston D.A., Selmaj K.W., Lake S.L., Moran S., Margolin D.H., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine 2008, 359:1786-1801.
9. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlen C., Goverman J. Apathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. Journal of Experimental Medicine 2001, 194:669-676.
10. Anderson A.C., Chandwaskar R., Lee D.H., Sullivan J.M., Solomon A., Rodriguez-Manzanet R., et al. Atransgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells. Journal of Immunology (Baltimore, Md: 1950) 2012, 188:2084-2092.
11. Reynolds J., Norgan V.A., Bhambra U., Smith J., Cook H.T., Pusey C.D. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. Journal of the American Society of Nephrology 2002, 13:359-369.
12. Zhang G.X., Ma C.G., Xiao B.G., Bakhiet M., Link H., Olsson T. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. European Journal of Immunology 1995, 25:1191-1198.
13. Larsson P., Holmdahl R., Klareskog L. Invivo treatment with anti-CD8 and anti-CD5 monoclonal antibodies alters induced tolerance to adjuvant arthritis. Journal of Cellular Biochemistry 1989, 40:49-56.
14. Raposo B.R., Rodrigues-Santos P., Carvalheiro H., Agua-Doce A.M., Carvalho L., Pereira da Silva J.A., et al. Monoclonal anti-CD8 therapy induces disease amelioration in the K/BxN mouse model of spontaneous chronic polyarthritis. Arthritis and Rheumatism 2010, 62:2953-2962.
15. McKinney E.F., Lyons P.A., Carr E.J., Hollis J.L., Jayne D.R., Willcocks L.C., et al. ACD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nature Medicine 2010, 16:586-591. 1p following 91.
16. Koh D.R., Ho A., Rahemtulla A., Fung-Leung W.P., Griesser H., Mak T.W. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. European Journal of Immunology 1995, 25:2558-2562.
17. Sharabi A., Mozes E. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. Journal of Immunology (Baltimore, Md: 1950) 2008, 181:3243-3251.
18. Filaci G., Bacilieri S., Fravega M., Monetti M., Contini P., Ghio M., et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. Journal of Immunology (Baltimore, Md: 1950) 2001, 166:6452-6457.
19. Longhi M.S., Hussain M.J., Bogdanos D.P., Quaglia A., Mieli-Vergani G., Ma Y., et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007, 46:472-484.
20. Chabot S., Fakhfakh A., Beland K., Lamarre A., Oldstone M.B., Alvarez F., et al. Mouse liver-specific CD8(+) T-cells encounter their cognate antigen and acquire capacity to destroy target hepatocytes. Journal of Autoimmunity 2012, 42:19-28.
21. Blanco P., Pitard V., Viallard J.F., Taupin J.L., Pellegrin J.L., Moreau J.F. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2005, 52:201-211.
22. Malmestrom C., Lycke J., Haghighi S., Andersen O., Carlsson L., Wadenvik H., et al. Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. Journal of Neuroimmunology 2008, 196:159-165.
23. Fujihara T., Fujita H., Tsubota K., Saito K., Tsuzaka K., Abe T., et al. Preferential localization of CD8+ alpha E beta 7+ T cells around acinar epithelial cells with apoptosis in patients with Sjogren's syndrome. Journal of Immunology (Baltimore, Md: 1950) 1999, 163:2226-2235.
24. Cherin P., Herson S., Crevon M.C., Hauw J.J., Cervera P., Galanaud P., et al. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. Journal of Rheumatology 1996, 23:1135-1142.
25. Giovanni F., Domenico P., Alessandro M., Raffaele I., Viviana N., Katia P.A., et al. Circulating CD8+CD56-perforin+ T cells are increased in multiple sclerosis patients. Journal of Neuroimmunology 2011, 240-241:137-141.
26. Kagi D., Odermatt B., Seiler P., Zinkernagel R.M., Mak T.W., Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. Journal of Experimental Medicine 1997, 186:989-997.
27. Tsai S., Shameli A., Santamaria P. CD8+ T cells in type 1 diabetes. Advances in Immunology 2008, 100:79-124.
28. Fox C.K., Furtwaengler A., Nepomuceno R.R., Martinez O.M., Krams S.M. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001, 21:272-279.
29. Kim J.S., Cho B.A., Sim J.H., Shah K., Woo C.M., Lee E.B., et al. IL-7Ralphalow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2012, 51:1587-1594.
30. Bretz J.D., Arscott P.L., Myc A., Baker J.R. Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. Journal of Biological Chemistry 1999, 274:25433-25438.
31. Cho B.A., Sim J.H., Park J.A., Kim H.W., Yoo W.H., Lee S.H., et al. Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis. Journal of Clinical Immunology 2012, 32:709-720.
32. Su X., Hu Q., Kristan J.M., Costa C., Shen Y., Gero D., et al. Significant role for Fas in the pathogenesis of autoimmune diabetes. Journal of Immunology (Baltimore, Md: 1950) 2000, 164:2523-2532.
33. Allison J., Thomas H.E., Catterall T., Kay T.W., Strasser A. Transgenic expression of dominant-negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced apoptosis and reduces spontaneous diabetes in nonobese diabetic mice. Journal of Immunology (Baltimore, Md: 1950) 2005, 175:293-301.
34. Chong M.M., Chen Y., Darwiche R., Dudek N.L., Irawaty W., Santamaria P., et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8+ T cell-mediated autoimmune destruction. Journal of Immunology (Baltimore, Md: 1950) 2004, 172:5714-5721.
35. Kreuwel H.T., Morgan D.J., Krahl T., Ko A., Sarvetnick N., Sherman L.A. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. Journal of Immunology (Baltimore, Md: 1950) 1999, 163:4335-4341.
36. Qin H., Trudeau J.D., Reid G.S., Lee I.F., Dutz J.P., Santamaria P., et al. Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. International Immunology 2004, 16:1657-1662.
37. Waldner H., Sobel R.A., Howard E., Kuchroo V.K. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md: 1950) 1997, 159:3100-3103.
38. Sabelko-Downes K.A., Cross A.H., Russell J.H. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. Journal of Experimental Medicine 1999, 189:1195-1205.
39. Suvannavejh G.C., Dal Canto M.C., Matis L.A., Miller S.D. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. Journal of Clinical Investigation 2000, 105:223-231.
40. Rus V., Nguyen V., Puliaev R., Puliaeva I., Zernetkina V., Luzina I., et al. Tcell TRAIL promotes murine lupus by sustaining effector CD4 Th cell numbers and by inhibiting CD8 CTL activity. Journal of Immunology (Baltimore, Md: 1950) 2007, 178:3962-3972.
41. Palma J.P., Lee H.G., Mohindru M., Kang B.S., Dal Canto M., Miller S.D., et al. Enhanced susceptibility to Theiler's virus-induced demyelinating disease in perforin-deficient mice. Journal of Neuroimmunology 2001, 116:125-135.
42. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946.
43. Lorenz H.M., Herrmann M., Winkler T., Gaipl U., Kalden J.R. Role of apoptosis in autoimmunity. Apoptosis: An International Journal on Programmed Cell Death 2000, 5:443-449.
44. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. American Journal of Pathology 2008, 172:146-155.
45. Huber M., Heink S., Pagenstecher A., Reinhard K., Ritter J., Visekruna A., et al. IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. Journal of Clinical Investigation 2013, 123:247-260.
46. Saxena A., Desbois S., Carrie N., Lawand M., Mars L.T., Liblau R.S. Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model. Journal of Immunology (Baltimore, Md: 1950) 2012, 189:3140-3149.
47. Hu Y., Ma D.X., Shan N.N., Zhu Y.Y., Liu X.G., Zhang L., et al. Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PloS One 2011, 6. e26522.
48. Hoyer K.K., Wolslegel K., Dooms H., Abbas A.K. Targeting T cell-specific costimulators and growth factors in a model of autoimmune hemolytic anemia. Journal of Immunology (Baltimore, Md: 1950) 2007, 179:2844-2850.
49. Hoyer K.K., Kuswanto W.F., Gallo E., Abbas A.K. Distinct roles of helper T-cell subsets in a systemic autoimmune disease. Blood 2009, 113:389-395.
50. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-1240.
51. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
52. Vizler C., Bercovici N., Heurtier A., Pardigon N., Goude K., Bailly K., et al. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts. Journal of Immunology (Baltimore, Md: 1950) 2000, 165:6314-6321.
53. Iezzi G., Boni A., Degl'Innocenti E., Grioni M., Bertilaccio M.T., Bellone M. Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses. Journal of Immunology (Baltimore, Md: 1950) 2006, 177:2131-2137.
54. Green E.A., Flavell R.A. The temporal importance of TNFalpha expression in the development of diabetes. Immunity 2000, 12:459-469.
55. Friese M.A., Jakobsen K.B., Friis L., Etzensperger R., Craner M.J., McMahon R.M., et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nature Medicine 2008, 14:1227-1235.
56. Uchimura K., Itoh M., Yamamoto K., Imamura S., Makino M., Kato T., et al. The effects of CD40- and interleukin (IL-4)-activated CD23+ cells on the production of IL-10 by mononuclear cells in Graves' disease: the role of CD8+ cells. Clinical and Experimental Immunology 2002, 128:308-312.
57. Ben-David H., Sharabi A., Dayan M., Sela M., Mozes E. The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:17459-17464.
58. Brusko T.M., Putnam A.L., Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunological Reviews 2008, 223:371-390.
59. Moore J.S., Calkins C.E. Invitro regulation of the pathogenic autoantibody response of New Zealand black mice. I. Loss with age of suppressive activity in T cell populations. Journal of Immunology (Baltimore, Md: 1950) 1985, 134:3838-3844.
60. Zhou Q.N., Xing L.M., Fu R., Wang H.Q., Liu H., Li L.J., et al. [Count and function of CD8(+)CXCR3(+) regulatory T cells in peripheral blood of patients with autoimmune hemolytic anemia]. Zhonghua yi xue za zhi 2011, 91:1687-1690.
61. Cosmi L., Liotta F., Lazzeri E., Francalanci M., Angeli R., Mazzinghi B., et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003, 102:4107-4114.
62. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. Afunction for interleukin 2 in Foxp3-expressing regulatory T cells. Nature Immunology 2005, 6:1142-1151.
63. Barron L., Dooms H., Hoyer K.K., Kuswanto W., Hofmann J., O'Gorman W.E., et al. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. Journal of Immunology (Baltimore, Md: 1950) 2010, 185:6426-6430.
64. Knoechel B., Lohr J., Kahn E., Bluestone J.A., Abbas A.K. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. Journal of Experimental Medicine 2005, 202:1375-1386.
65. Setoguchi R., Hori S., Takahashi T., Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. Journal of Experimental Medicine 2005, 201:723-735.
66. Shameli A., Yamanouchi J., Tsai S., Yang Y., Clemente-Casares X., Moore A., et al. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells. European Journal of Immunology 2013, 43:394-403.
67. Rifa'i M., Kawamoto Y., Nakashima I., Suzuki H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. Journal of Experimental Medicine 2004, 200:1123-1134.
68. Endharti A.T., Rifa I.M., Shi Z., Fukuoka Y., Nakahara Y., Kawamoto Y., et al. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. Journal of Immunology (Baltimore, Md: 1950) 2005, 175:7093-7097.
69. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. Journal of Experimental Medicine 1999, 190:995-1004.
70. Tang Q., Boden E.K., Henriksen K.J., Bour-Jordan H., Bi M., Bluestone J.A. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. European Journal of Immunology 2004, 34:2996-3005.
71. Scotto L., Naiyer A.J., Galluzzo S., Rossi P., Manavalan J.S., Kim-Schulze S., et al. Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28-T suppressor cells. Human Immunology 2004, 65:1297-1306.
72. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. Journal of Immunology (Baltimore, Md: 1950) 2003, 171:3348-3352.
73. Hoyer K.K., Dooms H., Barron L., Abbas A.K. Interleukin-2 in the development and control of inflammatory disease. Immunological Reviews 2008, 226:19-28.
74. Tai X., Cowan M., Feigenbaum L., Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nature Immunology 2005, 6:152-162.
75. Najafian N., Chitnis T., Salama A.D., Zhu B., Benou C., Yuan X., et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. Journal of Clinical Investigation 2003, 112:1037-1048.
76. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells invivo. Nature Immunology 2009, 10:1000-1007.
77. Klein L., Hinterberger M., Wirnsberger G., Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nature Reviews Immunology 2009, 9:833-844.
78. Anderson M.S., Su M.A. Aire and T cell development. Current Opinion in Immunology 2011, 23:198-206.
79. Devoss J.J., Shum A.K., Johannes K.P., Lu W., Krawisz A.K., Wang P., et al. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. Journal of Immunology (Baltimore, Md: 1950) 2008, 181:4072-4079.
80. Teh C.E., Daley S.R., Enders A., Goodnow C.C. T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14709-14714.
81. Pomié C., Vicente R., Vuddamalay Y., Lundgren B.A., van der Hoek M., Enault G., et al. Autoimmune regulator (AIRE)-deficient CD8+CD28low regulatory T lymphocytes fail to control experimental colitis. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:12437-12442.
82. Laakso S.M., Kekäläinen E., Rossi L.H., Laurinolli T.T., Mannerström H., Heikkilä N., et al. IL-7 dysregulation and loss of CD8+ T cell homeostasis in the monogenic human disease autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Journal of Immunology 2011, 187:2023-2030.
83. Perchellet A., Brabb T., Goverman J.M. Crosspresentation by nonhematopoietic and direct presentation by hematopoietic cells induce central tolerance to myelin basic protein. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:14040-14045.
84. Brynedal B., Duvefelt K., Jonasdottir G., Roos I.M., Akesson E., Palmgren J., et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PloS One 2007, 2. e664.
85. Rocha B., von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991, 251:1225-1228.
86. Schonrich G., Kalinke U., Momburg F., Malissen M., Schmitt-Verhulst A.M., Malissen B., et al. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991, 65:293-304.
87. Dubois P.M., Pihlgren M., Tomkowiak M., Van Mechelen M., Marvel J. Tolerant CD8 T cells induced by multiple injections of peptide antigen show impaired TCR signaling and altered proliferative responses invitro and invivo. Journal of Immunology (Baltimore, Md: 1950) 1998, 161:5260-5267.
88. Martin-Orozco N., Wang Y.H., Yagita H., Dong C. Cutting Edge: programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. Journal of Immunology (Baltimore, Md: 1950) 2006, 177:8291-8295.
89. Lohr J., Knoechel B., Nagabhushanam V., Abbas A.K. T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunological Reviews 2005, 204:116-127.
90. Frauwirth K.A., Alegre M.L., Thompson C.B. CTLA-4 is not required for induction of CD8(+) T cell anergy invivo. Journal of Immunology (Baltimore, Md: 1950) 2001, 167:4936-4941.
91. Voehringer D., Blaser C., Grawitz A.B., Chisari F.V., Buerki K., Pircher H. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. Journal of Immunology (Baltimore, Md: 1950) 2000, 165:2415-2422.
92. Kurts C., Sutherland R.M., Davey G., Li M., Lew A.M., Blanas E., et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:12703-12707.
93. Katzman S.D., O'Gorman W.E., Villarino A.V., Gallo E., Friedman R.S., Krummel M.F., et al. Duration of antigen receptor signaling determines T-cell tolerance or activation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:18085-18090.
94. Zajac A.J., Murali-Krishna K., Blattman J.N., Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Current Opinion in Immunology 1998, 10:444-449.
95. Redmond W.L., Hernandez J., Sherman L.A. Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC. Journal of Immunology (Baltimore, Md: 1950) 2003, 171:6349-6354.
96. Cohen J.N., Guidi C.J., Tewalt E.F., Qiao H., Rouhani S.J., Ruddell A., et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. Journal of Experimental Medicine 2010, 207:681-688.
97. Gardner J.M., Devoss J.J., Friedman R.S., Wong D.J., Tan Y.X., Zhou X., et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 2008, 321:843-847.
98. Lee J.W., Epardaud M., Sun J., Becker J.E., Cheng A.C., Yonekura A.R., et al. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nature Immunology 2007, 8:181-190.
99. Fletcher A.L., Lukacs-Kornek V., Reynoso E.D., Pinner S.E., Bellemare-Pelletier A., Curry M.S., et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. Journal of Experimental Medicine 2010, 207:689-697.
100. Nichols L.A., Chen Y., Colella T.A., Bennett C.L., Clausen B.E., Engelhard V.H. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. Journal of Immunology 2007, 179:993-1003.
101. Ouyang Q., Standifer N.E., Qin H., Gottlieb P., Verchere C.B., Nepom G.T., et al. Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes 2006, 55:3068-3074.
102. Baker C., Petrich de Marquesini L.G., Bishop A.J., Hedges A.J., Dayan C.M., Wong F.S. Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery. Journal of Clinical Immunology 2008, 28:350-360.
103. Zehn D., Bevan M.J. Tcells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006, 25:261-270.
104. Enouz S., Carrie L., Merkler D., Bevan M.J., Zehn D. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. Journal of Experimental Medicine 2012, 209:1769-1779.
105. Oldstone M.B., Nerenberg M., Southern P., Price J., Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319-331.
106. von Herrath M.G., Dockter J., Oldstone M.B. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994, 1:231-242.
107. von Herrath M.G., Dockter J., Nerenberg M., Gairin J.E., Oldstone M.B. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. Journal of Experimental Medicine 1994, 180:1901-1910.
108. Gronski M.A., Boulter J.M., Moskophidis D., Nguyen L.T., Holmberg K., Elford A.R., et al. TCR affinity and negative regulation limit autoimmunity. Nature Medicine 2004, 10:1234-1239.
109. Amrani A., Verdaguer J., Serra P., Tafuro S., Tan R., Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000, 406:739-742.
110. Han B., Serra P., Amrani A., Yamanouchi J., Maree A.F., Edelstein-Keshet L., et al. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nature Medicine 2005, 11:645-652.
111. Ford M.L., Evavold B.D. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. European Journal of Immunology 2005, 35:76-85.
112. Christen U., von Herrath M.G. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Molecular Immunology 2004, 40:1113-1120.
113. Srinivasappa J., Saegusa J., Prabhakar B.S., Gentry M.K., Buchmeier M.J., Wiktor T.J., et al. Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. Journal of Virology 1986, 57:397-401.
114. Ang C.W., Jacobs B.C., Laman J.D. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends in Immunology 2004, 25:61-66.
115. Ohashi P.S., Oehen S., Buerki K., Pircher H., Ohashi C.T., Odermatt B., et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305-317.
116. Harkonen T., Paananen A., Lankinen H., Hovi T., Vaarala O., Roivainen M. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans. Journal of Medical Virology 2003, 69:426-440.
117. Hiemstra H.S., Schloot N.C., van Veelen P.A., Willemen S.J., Franken K.L., van Rood J.J., et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:3988-3991.
118. Honeyman M.C., Stone N.L., Falk B.A., Nepom G., Harrison L.C. Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens. Journal of Immunology (Baltimore, Md: 1950) 2010, 184:2204-2210.
119. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
120. Zhao Z.S., Granucci F., Yeh L., Schaffer P.A., Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998, 279:1344-1347.
121. Gross D.M., Forsthuber T., Tary-Lehmann M., Etling C., Ito K., Nagy Z.A., et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998, 281:703-706.
122. Yasuoka H., Okazaki Y., Kawakami Y., Hirakata M., Inoko H., Ikeda Y., et al. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behçet's disease. Arthritis and Rheumatism 2004, 50:3658-3662.
123. Alam S.M., Gascoigne N.R. Posttranslational regulation of TCR Valpha allelic exclusion during T cell differentiation. Journal of Immunology 1998, 160:3883-3890.
124. Corthay A., Nandakumar K.S., Holmdahl R. Evaluation of the percentage of peripheral T cells with two different T cell receptor alpha-chains and of their potential role in autoimmunity. Journal of Autoimmunity 2001, 16:423-429.
125. Padovan E., Casorati G., Dellabona P., Meyer S., Brockhaus M., Lanzavecchia A. Expression of two T cell receptor alpha chains: dual receptor T cells. Science 1993, 262:422-424.
126. He X., Janeway C.A., Levine M., Robinson E., Preston-Hurlburt P., Viret C., et al. Dual receptor T cells extend the immune repertoire for foreign antigens. Nature Immunology 2002, 3:127-134.
127. Morris G.P., Allen P.M. Cutting edge: highly alloreactive dual TCR T cells play a dominant role in graft-versus-host disease. Journal of Immunology 2009, 182:6639-6643.
128. Ji Q., Perchellet A., Goverman J.M. Viral infection triggers central nervous system autoimmunity via activation of CD8+ T cells expressing dual TCRs. Nature Immunology 2010, 11:628-634.
129. Kim S.M., Bhonsle L., Besgen P., Nickel J., Backes A., Held K., et al. Analysis of the paired TCR alpha- and beta-chains of single human T cells. PloS One 2012, 7. e37338.
130. Rottembourg D., Deal C., Lambert M., Mallone R., Carel J.C., Lacroix A., et al. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease. Journal of Autoimmunity 2010, 35:309-315.
131. Nakao H., Eguchi K., Kawakami A., Migita K., Otsubo T., Ueki Y., et al. Phenotypic characterization of lymphocytes infiltrating synovial tissue from patients with rheumatoid arthritis: analysis of lymphocytes isolated from minced synovial tissue by dual immunofluorescent staining. Journal of Rheumatology 1990, 17:142-148.
132. Peng S.L., Moslehi J., Robert M.E., Craft J. Perforin protects against autoimmunity in lupus-prone mice. Journal of Immunology (Baltimore, Md: 1950) 1998, 160:652-660.
133. Alli R., Nguyen P., Boyd K., Sundberg J.P., Geiger T.L. Amouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. Journal of Immunology (Baltimore, Md: 1950) 2012, 188:477-486.
134. Auger J.L., Haasken S., Steinert E.M., Binstadt B.A. Incomplete TCR-beta allelic exclusion accelerates spontaneous autoimmune arthritis in K/BxN TCR transgenic mice. European Journal of Immunology 2012, 42:2354-2362.
135. Elliott J.I., Altmann D.M. Dual T cell receptor alpha chain T cells in autoimmunity. Journal of Experimental Medicine 1995, 182:953-959.
136. Sarukhan A., Garcia C., Lanoue A., von Boehmer H. Allelic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors. Immunity 1998, 8:563-570.
137. Fossati G., Cooke A., Papafio R.Q., Haskins K., Stockinger B. Triggering a second T cell receptor on diabetogenic T cells can prevent induction of diabetes. Journal of Experimental Medicine 1999, 190:577-583.
138. Libbey J.E., Cusick M.F., Tsunoda I., Fujinami R.S. Antiviral CD8(+) T cells cause an experimental autoimmune encephalomyelitis-like disease in naive mice. Journal of Neurovirology 2012, 18:45-54.
139. Seki S.S., Sugimura K., Ota M., Matsuzawa J., Katsuyama Y., Ishizuka K., et al. Stratification analysis of MICA triplet repeat polymorphisms and HLA antigens associated with ulcerative colitis in Japanese. Tissue Antigens 2001, 58:71-76.
140. Harrison L.C., Dempsey-Collier M., Kramer D.R., Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. Journal of Experimental Medicine 1996, 184:2167-2174.
141. Lee Y.H., Ishida Y., Rifa'i M., Shi Z., Isobe K., Suzuki H. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md: 1950) 2008, 180:825-832.
142. Antel J., Bania M., Noronha A., Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. Journal of Immunology (Baltimore, Md: 1950) 1986, 137:3436-3439.
143. Davila E., Kang Y.M., Park Y.W., Sawai H., He X., Pryshchep S., et al. Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis. Journal of Immunology (Baltimore, Md: 1950) 2005, 174:7292-7301.
144. Tulunay A., Yavuz S., Direskeneli H., Eksioglu-Demiralp E. CD8+CD28-, suppressive T cells in systemic lupus erythematosus. Lupus 2008, 17:630-637.
145. Ho J., Kurtz C.C., Naganuma M., Ernst P.B., Cominelli F., Rivera-Nieves J. ACD8+/CD103high T cell subset regulates TNF-mediated chronic murine ileitis. Journal of Immunology (Baltimore, Md: 1950) 2008, 180:2573-2580.
146. Kerkar N., Choudhuri K., Ma Y., Mahmoud A., Bogdanos D.P., Muratori L., et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. Journal of Immunology (Baltimore, Md: 1950) 2003, 170:1481-1489.
147. Ehser J., Holdener M., Christen S., Bayer M., Pfeilschifter J.M., Hintermann E., et al. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. Journal of Autoimmunity 2013, 42:39-49.
148. Ohashi H., Okugawa T., Itoh M. Circulating activated T cell subsets in autoimmune thyroid diseases: differences between untreated and treated patients. Acta Endocrinologica 1991, 125:502-509.
149. Gershwin M.E., Shoenfeld Y. Chella David: a lifetime contribution in translational immunology. Journal of Autoimmunity 2011, 37:59-62.
150. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. Journal of Autoimmunity 2012, 39:117-120.
151. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. Journal of Autoimmunity 2012, 39:4-8.